Psychedelics can profoundly alter perception, emotion, cognition and our sense of self.
Research across psychedelic compounds is exploring their potential to create periods of increased psychological flexibility, emotional openness and new perspectives on deeply established patterns.
But what makes psychedelic therapy particularly interesting is not simply the experience itself.
It is what may become possible when that experience is held within a therapeutic relationship.
Research from leading institutions including Johns Hopkins, Imperial College London and Yale has contributed to a growing evidence base around psychedelic-assisted therapy and its potential in areas including depression, anxiety and psychological distress.
The science is still evolving. But one thing is becoming increasingly clear:
The psychedelic is not the whole therapy.
The Science of Psychedelics with Dr David Luke
Afterlight focuses on psilocybin.
Psilocybin is converted by the body into psilocin, the active compound responsible for its primary psychedelic effects.
Psilocin acts primarily on serotonin 5-HT2A receptors in the brain, influencing communication between brain networks and temporarily altering patterns of perception, cognition and emotional processing. Research into these changes, including altered network connectivity, is helping scientists better understand how psychedelic experiences may support psychological change.
Psilocybin is one of the most extensively studied classic psychedelics in modern clinical research, with studies investigating its potential across depression, anxiety, addiction and other areas of psychological distress.
There is also a growing evidence base around its safety and tolerability. Systematic reviews suggest that psilocybin is generally well tolerated when administered in controlled settings with appropriate screening, preparation and support.
A 2024 systematic review and meta-analysis comparing psychedelics across mental health conditions found that "psilocybin showed the strongest therapeutic effect among four psychedelics" included in the analysis.
This finding should not be interpreted as proving psilocybin is universally superior; the evidence and study designs varied across compounds and conditions.
For Afterlight, psilocybin offers a well-researched foundation for exploring meaningful psychological change — with the clinical framework around the experience treated as seriously as the experience itself.
Psilocybin (Psychedelic) Therapy at Johns Hopkins University
The medicine matters. So does the person. The relationship. The environment. And what happens afterwards.
Research increasingly points to the importance of these factors in shaping psychedelic experiences and their therapeutic outcomes.
Our approach is informed not only by research into the potential benefits of psychedelics, but also by research into what can happen when experiences become difficult.
Prof. David Luke's Challenging Psychedelic Experiences Project investigates the psychological difficulties that can emerge during and after psychedelic experiences — and what helps people navigate them.
This perspective is central to Afterlight.
We don't design only for the peak experience.
We design for the person, the experience and everything that surrounds it.
Informed by the work of Prof. David Luke and the Challenging Psychedelic Experiences Project, University of Greenwich.
Six factors that shape the work
The substance, dose and formulation.
Afterlight carefully considers the medicine itself and how it is administered, with attention to dosage, effects, safety and individual response.
Want to understand the science more deeply? Learn more on How Psilocybin Changes the Brain.
Psychological history, intentions, readiness and mindset.
Afterlight begins with the person, not simply the protocol. Your psychological history, current context and intentions inform how we understand your needs and approach the experience.
Trust, therapeutic alliance and clinical presence.
The relationship between participant and clinician is not incidental to psychedelic-assisted therapy. Research has linked stronger therapeutic alliance with better treatment outcomes, reinforcing the importance of the relationship across the therapeutic process.
At Afterlight, the therapeutic relationship is at the centre of the work.
Safety, setting, music, support and context.
The context in which a psychedelic experience takes place can influence how it is experienced and understood.
Afterlight deliberately designs the environment around psychological safety, presence and support.
What happens during the psychedelic experience.
No two experiences are identical. Emotion, memory, sensation, insight and uncertainty can all arise — sometimes in unexpected ways.
Clinical presence matters throughout. Our role is not to direct the experience, but to create the conditions for you to move through it safely, with skilled support when you need it.
Integration first. AfterCare when the work needs to go further.
The experience does not end when the effects wear off. Integration creates space to reflect on what emerged and begin making meaning from it — informed by Dr. Rosalind Watts’ Pearl Dive framework, a powerful way of working with the insights, the “pearls”, that can emerge from psychedelic experiences.
AfterCare is what comes next: our six-session clinical programme takes those pearls and builds from them, exploring what they reveal, working therapeutically with what needs to shift, defining meaningful goals and creating a personalised roadmap for continued change.
The experience opens the door. Integration helps you understand what you found. AfterCare helps you build from it.
Good psychedelic care isn't only about creating the conditions for a meaningful experience. It's about having experienced clinicians who know how to support whatever emerges.
Informed by the work of Prof. David Luke and the Challenging Psychedelic Experiences Project, University of Greenwich.
The quality of the experience matters.
So does everything around it.
A psychedelic experience can be profound. But what happens before, during and after it can influence how that experience is understood, processed and carried forward.
Research on psilocybin-assisted therapy has found meaningful associations between the therapeutic relationship and outcomes months after the psychedelic experience itself.
This is why Afterlight doesn't see the psychedelic experience as a standalone event.
We give the experience somewhere to go.
Integration creates space to process what emerged — making sense of new perspectives, emotions and discoveries.
AfterCare provides continued psychological support to work with those insights and begin translating them into everyday life.
The goal isn't to prolong the psychedelic experience.
It's to help meaningful experiences become meaningful change.
Afterlight brings together:
We stay close to the evidence while recognising where psychedelic science is still developing.
We believe people considering psychedelic therapy deserve access to the evidence behind it — not just the promises surrounding it.
Meet Afterlight Clinical, an AI-powered clinical copilot designed to help practitioners and clinics navigate the psychological complexity of psychedelic-assisted therapy.
Discover CopilotAfterlight Clinical(opens in a new tab)
This is Afterlight
We assess before we recommend. We prepare you carefully. We hold the experience with you. And we stay with the work that follows. If you’re ready to explore what’s next, start with a conversation about you.